2,5-Dimethoxy-4-cyanoamphetamine (DOCN) is a serotonergic drug of the phenethylamine, amphetamine, and DOx families. It is a DOx derivative with a cyano group (–C≡N) at the 4position of the molecule.
Use and effects The effects of DOCN in humans and whether it is a psychedelic are unknown.
Interactions
Pharmacology DON shows much lower affinities for the serotonin 5-HT2 receptors than other DOx drugs. However, DOCN also showed by far the greatest degree of selectivity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor (22-fold) of any other assessed DOx drug. Applying this strategy (i.e., cyano substitution) to the 25-NB series resulted in the discovery of 25CN-NBOH, one of the most selective serotonin 5-HT2A receptor agonists discovered to date.
Chemistry Analogues Related drugs include DON, 2C-N, DOA, 2C-CN, 25CN-NBOH, and 25CN-NBOMe.
History DOCN was first described in the scientific literature by Richard Glennon and colleagues by 1989.
Society and culture Legal status Canada DOCN is a controlled substance in Canada under phenethylamine blanket-ban language.
United States DOCN is not a controlled substance in the United States as of 2011.
See also DOx (psychedelics) 2C-N 2C-CN 25CN-NBOH 25CN-NBOMe
References
External links DOCN - isomer design